SCHEMBL5249393

SCHEMBL5249393

Nc1onc2c(OC(F)(F)F)ccc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 19/20 0.63
FLT3 P36888 17/20 0.63
KIT P10721 15/20 0.63
CSF1R P07333 6/20 0.63
FLT1 P17948 6/20 0.63
TEK Q02763 2/20 0.63
PDGFRB P09619 4/20 0.57
LCK P06239 4/20 0.52
LYN P07948 4/20 0.52
FLT4 P35916 4/20 0.52
BLK P51451 4/20 0.52
FYN P06241 3/20 0.52
SRC P12931 2/20 0.52
ABL1 P00519 1/20 0.52
AURKA O14965 3/20 0.50
ROCK2 O75116 3/20 0.50
RPS6KA5 O75582 3/20 0.50
NTRK1 P04629 3/20 0.50
RET P07949 3/20 0.50
FGFR1 P11362 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5254655 0.89 KDR (0.63) KDRFLT3KITCSF1RFLT1
SCHEMBL5249636 0.89 KDR (0.67) KDRFLT3KITCSF1RFLT1
SCHEMBL1379867 0.88 KDR (0.77) KDRFLT3KITCSF1RFLT1
SCHEMBL425935 0.88 KDR (0.79) KDRFLT3KITCSF1RFLT1
SCHEMBL1382149 0.86 KDR (0.65) KDRFLT3KITCSF1RFLT1
SCHEMBL5252618 0.86 KDR (0.60) KDRFLT3KITCSF1RFLT1
SCHEMBL1380250 0.86 KDR (0.65) KDRFLT3KITCSF1RFLT1
SCHEMBL4735746 0.85 KDR (0.68) KDRFLT3KITCSF1RFLT1
SCHEMBL5253491 0.82 KDR (0.64) KDRFLT3KITCSF1RFLT1
SCHEMBL5256129 0.82 KDR (0.79) KDRFLT3KITCSF1RFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP disclosed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO disclosed